Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Core Insights - Genelux Corporation is entering a pivotal period in 2026 with key clinical readouts for Olvi-Vec, particularly from the Phase 3 OnPrime/GOG-3076 trial expected in the second half of the year [2] - Interim data from systemic lung cancer trials show promising results, with partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC) [2][3] - The company appointed Jason Litten, M.D., as Chief Medical Officer to lead the clinical development strategy [6] - As of December 31, 2025, the company reported $33.1 million in pro forma cash and equivalents, expected to support operations into the first quarter of 2027 [8] Clinical Development - The ongoing Phase 3 OnPrime/GOG-3076 trial is evaluating Olvi-Vec in combination with platinum-doublet chemotherapy and bevacizumab for platinum-resistant/refractory ovarian cancer, with topline data anticipated in the second half of 2026 [4] - Interim results from the SCLC Phase 1b/2 trial showed a 33% partial response rate among patients, with a disease control rate of 67% [10] - The Phase 2 VIRO-25 trial in NSCLC reported a 60% disease control rate, with tumor size changes observed [10] Financial Performance - For the year ended December 31, 2025, Genelux reported a net loss of $32.1 million, or $0.86 per share, compared to a net loss of $29.9 million, or $0.95 per share, for 2024 [11][17] - Research and development expenses increased to $19.9 million in 2025 from $19.0 million in 2024, primarily due to higher clinical trial costs [9] - General and administrative expenses rose to $13.4 million in 2025 from $12.7 million in 2024, driven by increased employee compensation [10] Business Updates - The company successfully closed an underwritten public offering in January 2026, raising $18.5 million in net proceeds, which will be used for general corporate purposes [7] - The appointment of Jason Litten, M.D., as Chief Medical Officer is expected to enhance the company's clinical development strategy, leveraging his extensive experience in clinical trials [6]